OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
1 clinical trials · Condition
◉ Watch OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
| Record | Firm | Date |
|---|---|---|
| Clinical Study of OR for Second-line Treatment of Refractory MZL (NCT06134284) | Lixia Sheng | 2023-01-02 |
Track OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.